“…271, 272, 273, 274, 275, 276 The intrinsic risk of AKI with the administration of aminoglycosides has led some authors to call for elimination of aminoglycosides as a therapeutic option in current clinical management of infectious diseases. 277 The anticipated demise of aminoglycosides from our therapeutic armamentarium has not occurred, however, in light of recent developments with progressive antimicrobial resistance to beta-lactams, quinolones, and a number of other classes of antimicrobial agents.…”